Lukas Biomedical Inc. (TPEX:6814)

Market Cap	1.06B +17.9%
Revenue (ttm)	179.49M -16.1%
Net Income	-85.63M
EPS	-2.05
Shares Out	41.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25
Average Volume	21,945
Open	25.35
Previous Close	25.35
Day's Range	24.15 - 25.35
52-Week Range	20.00 - 32.50
Beta	0.12
RSI	48.39
Earnings Date	May 11, 2026

About Lukas Biomedical

Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments. It also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distributes immune cell therapy culture technology; and leases building equipment. In addition, the company involved in the new immune cell research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 96
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6814

Financial Performance

In 2025, Lukas Biomedical's revenue was 179.49 million, a decrease of -5.44% compared to the previous year's 189.83 million. Losses were -85.63 million, -9.27% less than in 2024.